{"log_id": 2917952650030859404, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 3e-06, "average": 0.997218, "min": 0.995542}, "location": {"width": 44, "top": 204, "height": 25, "left": 292}, "words": "罕见"}, {"probability": {"variance": 2e-06, "average": 0.998129, "min": 0.996585}, "location": {"width": 64, "top": 203, "height": 25, "left": 550}, "words": "尿失禁"}, {"probability": {"variance": 0.001848, "average": 0.956618, "min": 0.913633}, "location": {"width": 31, "top": 184, "height": 54, "left": 1142}, "words": "总生"}, {"probability": {"variance": 3.5e-05, "average": 0.9969, "min": 0.96515}, "location": {"width": 740, "top": 294, "height": 27, "left": 267}, "words": "文拉法辛被突然停用、剂量降低或逐渐减少时,有报道以下的症状:轻躁狂、焦虑、激"}, {"probability": {"variance": 0.000103, "average": 0.994254, "min": 0.948339}, "location": {"width": 761, "top": 339, "height": 26, "left": 225}, "words": "越、神经质、意识模糊、失眠或其它睡眠障碍、疲劳、嗜睡、感觉异常、头晕、惊厥、眩晕"}, {"probability": {"variance": 0.004919, "average": 0.980072, "min": 0.623498}, "location": {"width": 779, "top": 385, "height": 26, "left": 226}, "words": "头痛、流行性感冒样症状、耳鸣、协调和平衡障碍、震颤、出汗、口干、厌食、腹泻、恶心"}, {"probability": {"variance": 9.9e-05, "average": 0.995158, "min": 0.959248}, "location": {"width": 710, "top": 430, "height": 25, "left": 227}, "words": "或呕吐。在上市前的研究中,绝大多数的停药反应是轻度的并且无需治疗即可恢复"}, {"probability": {"variance": 0, "average": 0.999149, "min": 0.998803}, "location": {"width": 66, "top": 479, "height": 23, "left": 234}, "words": "【禁忌】"}, {"probability": {"variance": 0.001354, "average": 0.989644, "min": 0.810122}, "location": {"width": 472, "top": 521, "height": 25, "left": 263}, "words": "1.本品禁用于对盐酸文拉法辛或任何赋形剂过敏的患者"}, {"probability": {"variance": 0.002708, "average": 0.984389, "min": 0.727139}, "location": {"width": 741, "top": 565, "height": 25, "left": 265}, "words": "2.本品禁用于同时服用 MAOS的患者:在停用 MAOIS后至少14天内不得开始使用文"}, {"probability": {"variance": 0.000704, "average": 0.990934, "min": 0.86396}, "location": {"width": 778, "top": 610, "height": 25, "left": 228}, "words": "拉法辛,对于可逆性单胺氧化酶抑制剂,此间期可相应缩短(参考可逆性单胺氧化酶抑制剂"}, {"probability": {"variance": 0.001442, "average": 0.986437, "min": 0.830643}, "location": {"width": 572, "top": 654, "height": 25, "left": 227}, "words": "的说明书);停用文拉法辛至少7天后方可开始以 MAOIS进行治疗"}, {"probability": {"variance": 3e-06, "average": 0.998049, "min": 0.995002}, "location": {"width": 70, "top": 699, "height": 24, "left": 232}, "words": "【警告】"}, {"probability": {"variance": 0.003052, "average": 0.980534, "min": 0.782905}, "location": {"width": 256, "top": 745, "height": 25, "left": 225}, "words": "1.临床症状的恶化和自杀风险"}, {"probability": {"variance": 2.5e-05, "average": 0.997557, "min": 0.978364}, "location": {"width": 725, "top": 788, "height": 26, "left": 268}, "words": "患有抑郁症的成年和儿童患者,无论是否服用抗抑郁药物,他们的抑郁症都有可能恶化"}, {"probability": {"variance": 8.1e-05, "average": 0.995888, "min": 0.948709}, "location": {"width": 777, "top": 833, "height": 26, "left": 228}, "words": "并有可能出现自杀意念和自杀行为以及行为异常变化,这种风险一直会持续到病情发生明显"}, {"probability": {"variance": 4.6e-05, "average": 0.996585, "min": 0.962809}, "location": {"width": 776, "top": 877, "height": 25, "left": 229}, "words": "缓解时为止。已知抑郁和某些精神障碍与自杀风险有关,并且这些精神障碍本身为自杀的最"}, {"probability": {"variance": 0.000698, "average": 0.991907, "min": 0.83659}, "location": {"width": 779, "top": 921, "height": 26, "left": 227}, "words": "强的预兆。然而,长期以来一直有这些的担忧:在某些患者治疗早期,抗抑郁药物可能对诱"}, {"probability": {"variance": 0.001205, "average": 0.98674, "min": 0.809481}, "location": {"width": 778, "top": 965, "height": 28, "left": 227}, "words": "导抑郁症状恶化,以及产生自杀意念、行为中起着作用。抗抑郁药物( SSRIS和其他)短期"}, {"probability": {"variance": 0.000395, "average": 0.993129, "min": 0.905671}, "location": {"width": 772, "top": 1011, "height": 26, "left": 228}, "words": "安慰剂对照研究汇总分析显示,在患有抑郁症(MDD)和其它精神障碍的儿童、青少年和"}, {"probability": {"variance": 0.001159, "average": 0.987904, "min": 0.834056}, "location": {"width": 777, "top": 1054, "height": 26, "left": 228}, "words": "青年(18~24岁)中,与安慰剂相比,抗抑郁药物增加了产生自杀想法和实施自杀行为(自"}, {"probability": {"variance": 0.006271, "average": 0.970918, "min": 0.679977}, "location": {"width": 778, "top": 1096, "height": 37, "left": 228}, "words": "杀意念、行为)的风险,但短期的临床试验没有显示,在年龄大于24岁的成年人安"}, {"probability": {"variance": 0.003196, "average": 0.979259, "min": 0.729687}, "location": {"width": 767, "top": 1139, "height": 30, "left": 228}, "words": "慰剂相比,使用抗抑郁药物会增加自杀意念、行为的风险;在年龄65岁及以上的成年人中"}, {"probability": {"variance": 0.000374, "average": 0.994146, "min": 0.905331}, "location": {"width": 455, "top": 1186, "height": 26, "left": 229}, "words": "使用抗抑郁药物后,自杀意念、行为的风险有所降低"}, {"probability": {"variance": 0.000166, "average": 0.995416, "min": 0.9257}, "location": {"width": 736, "top": 1225, "height": 32, "left": 269}, "words": "在患有抑郁症、强迫症(OCD)或其它精神障碍的儿童和青少年中进行的安慰剂对照"}, {"probability": {"variance": 0.002482, "average": 0.984096, "min": 0.684576}, "location": {"width": 776, "top": 1273, "height": 29, "left": 229}, "words": "试验(共计24项短期临床试验,9种抗抑郁药物,包括愈4400例患者)和在患有抑郁症或其"}, {"probability": {"variance": 2.5e-05, "average": 0.997635, "min": 0.970613}, "location": {"width": 777, "top": 1319, "height": 29, "left": 229}, "words": "它精神障碍的成年患者中进行的安慰剂对照试验(共计295项短期临床试验(中位持续时间"}, {"probability": {"variance": 0.001108, "average": 0.986703, "min": 0.814293}, "location": {"width": 776, "top": 1365, "height": 27, "left": 229}, "words": "为2个月),11种抗抑郁药物,愈7700患者),各种药物引起的自杀意念、行为的风险有很"}, {"probability": {"variance": 5.3e-05, "average": 0.996621, "min": 0.967471}, "location": {"width": 777, "top": 1409, "height": 28, "left": 228}, "words": "大的差异,但是大部分的药物研究显现出较年轻患者自杀意念、行为风险增加的趋势。在各"}, {"probability": {"variance": 6.1e-05, "average": 0.99736, "min": 0.95099}, "location": {"width": 776, "top": 1454, "height": 26, "left": 229}, "words": "个不同的适应症中,自杀意念、行为的绝对风险不同,在抑郁症中的绝对风险最高。虽然在"}, {"probability": {"variance": 0.000247, "average": 0.993973, "min": 0.911732}, "location": {"width": 776, "top": 1498, "height": 26, "left": 229}, "words": "各个适应症中的绝对风险有所不同(药物和安慰剂相比),但是,在不同适应症的年龄层中"}], "language": 3}